Jubilant Pharmova Limited, a global integrated pharmaceutical company, has announced its financial results for the fourth quarter (Q4) and fiscal year ending March 31, 2024 (FY24).
Q4FY24 Financial Highlights:
Total Income: ₹1,773 crore (5% increase compared to Q4FY23)
Reported EBITDA: ₹289 crore (20% increase compared to Q4FY23)
EBITDA margin: 16.3% (Increased by 200 basis points compared to Q4FY23)
Normalized PAT: ₹61 crore (122% decrease compared to Q4FY23)
Consolidated Net Loss: Narrowed to ₹5.86 crore (improved from ₹9.79 crore loss in Q4FY23)
Sales: Increased by 5% to ₹1,746 crore, with the radiopharma business seeing an 18.6% rise
FY24 Financial Highlights:
Total Income: ₹6,772 crore (7% increase compared to FY23)
Reported EBITDA: ₹994 crore (20% increase compared to FY23)
EBITDA margin: 14.7% (Increased by 160 basis points compared to FY23)
Normalized PAT: ₹195 crore (63% increase compared to FY23)
Key Points:
Improved Performance: The company demonstrated strong growth in both revenue and EBITDA in FY24, showcasing improved operational efficiency and profitability.
Radiopharma Business: The radiopharma business played a crucial role in driving revenue growth, especially in the fourth quarter.
Narrowed Net Loss: Despite a decline in normalized PAT in Q4FY24, the company managed to narrow its consolidated net loss.
Dividend Announcement: The Board of Directors proposed a dividend of ₹5 per equity share for FY24.
Additional Insights:
Jubilant Pharmova's focus on high-growth areas like radiopharmaceuticals and contract manufacturing is paying off.
The company is optimistic about its future prospects and plans to launch new products in the radiopharma segment.
The management highlighted the company's strong track record and commitment to innovation as key drivers for future growth.
For further information and analysis, you can refer to the following resources:
Jubilant Pharmova Limited Official Website (Investor Relations): https://www.jubilantpharmova.com/investors/financials/quarterly-results
ICICI Direct Analysis: https://www.icicidirect.com/stocks/jubilant-pharmova-ltd-share-price
5paisa Share Price: https://www.5paisa.com/stocks/jublpharma-share-price
Comments